Baker Bros. Advisors Reduces $10M in Tectonic Therapeutic, Inc. ($TECX)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors reduced its position in Tectonic Therapeutic, Inc. ($TECX) by 32.72% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 607,788 shares of Tectonic Therapeutic, Inc. after selling 295,612 shares during the quarter. Baker Bros. Advisors's holdings in Tectonic Therapeutic, Inc. were worth $20.90 million as of its most recent filing.
Tectonic Therapeutic, Inc. Stock Down 3.5%
Shares of Tectonic Therapeutic, Inc. ($TECX) traded around $34.38 on Saturday, down 3.5% for the day.
Tectonic Therapeutic, Inc. Earnings
Analysts Set New Price Targets
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Get Tectonic Therapeutic, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TECX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.